申请人:Beecham Group p.l.c.
公开号:EP0431741A2
公开(公告)日:1991-06-12
Compounds of formula (I) and pharmaceutically acceptable salts thereof:
wherein
a and b together form an -O- or -CH₂- linkage or a bond;
either Y is N and R₂ is hydrogen; or
Y is C-R₁
wherein
either one of R₁ and R₂ is hydrogen and the other is nitro, cyano, halo, CF₃, C₂F₅, formyl, aldoxime, CF₃O, NO₂-CH=CH-, NC-CH=CH-; a group RxX- wherein Rx is C₁₋₆ alkyl, aryl or heteroaryl either of which may be optionally substituted by one, two or three of C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo, CF₃ and cyano; and X is C=O, O.C=O, C=O.O, CHOH, SO, SO₂, O.SO, O.SO₂, CONH, O.CONH, C=S, O.C=S, C=S.O, CH.SH, SONH, SO₂NH, O.SONH, 0.SO₂NH, CO-CH=CH, C=NHOH, C=NNH₂; or a group RyRzNZ- wherein Ry and Rz are independently hydrogen or C₁₋₆ alkyl and Z is C=O, SO or SO₂; or a group (RwO)₂P(O)W wherein Rw is hydrogen or C₁₋₆ alkyl and W is O or a bond; or
R₁ is a C₃₋₈ cycloalkyl group or a C₁₋₆ alkyl group optionally substituted by a group which is hydroxy, C₁₋₆ alkoxy, amino optionally substituted by one or two C₁₋₆ alkyl groups, C₁₋₇ alkanoylamino, C₃₋₈ cycloalkyloxy or C₃₋₈ cycloalkylamino; and R₂ is hydrogen; or one of R₁ and R₂ is nitro, cyano or C₁₋₃ alkylcarbonyl and the other is a different group selected from nitro, cyano, halo, C₁₋₃ alkylcarbonyl, methoxy or amino optionally substituted by one or two C₁₋₆ alkyl or by C₂₋₇ alkanoyl; or
R₁ and R₂ together with the carbon atoms to which they are attached, form 2,1,3-oxadiazole or triazole; either one of R₃ and R₄ is hydrogen or C₁₋₄ alkyl and the other is C₁₋₄ alkyl; or
R₃ and R₄ together are C₂₋₅ polymethylene;
R₅ is hydrogen, hydroxy, C₁₋₆ alkoxy, C₁₋₇ acyloxy or ONO₂;
R₆ is hydrogen or C₁₋₆ alkyl; and
R₇ is halo, amino or methylamino;
which are K⁺ channel activators, useful in the treatment of hypertension and respiratory tract disorders.
式 (I) 的化合物及其药学上可接受的盐类:
其中
a 和 b 共同形成 -O- 或 -CH₂- 连接或键;
Y 是 N 且 R₂ 是氢;或
Y 是 C-R₁
其中
R₁ 和 R₂ 中的一个是氢,另一个是硝基、氰基、卤素、CF₃、 C₂F₅、甲酰基、醛肟、CF₃O、NO₂-CH=CH-、NC-CH=CH-;基团 RxX-,其中 Rx 是 C₁₋₆烷基、芳基或杂芳基,其中任一个可被一个、两个或三个 C₁₋₄烷基、C₁₋₄烷氧基、硝基、卤代、CF₃ 和氰基任选取代;且 X 是 C=O、O.c=o, c=o.o, choh, so, so₂, o.so, o.so₂, conh, o.conh, c=s, o.c=s, c=s.o, ch.sh, sonh, so₂nh, o.sonh, 0.SO₂NH、CO-CH=CH、C=NHOH、C=NNH₂;或基团 RyRzNZ-,其中 Ry 和 Rz 独立地为氢或 C₁₋₆烷基,Z 为 C=O、SO 或 SO₂;或基团 (RwO)₂P(O)W,其中 Rw 是氢或 C₁₋₆ 烷基,W 是 O 或键;或
R₁ 是 C₃₋₈ 环烷基或任选被羟基、C₁₋₆ 烷氧基取代的 C₁₋₆ 烷基、可选择被一个或两个 C₁₋₆烷基、C₁₋₇烷酰氨基、C₃₋₈ 环烷氧基或 C₃₋₈ 环烷基氨基取代的氨基;且 R₂ 为氢;或 R₁ 和 R₂ 中的一个是硝基、氰基或 C₁₋₃烷基羰基,另一个是选自硝基、氰基、卤代、C₁₋₃烷基羰基的不同基团、卤素、C₁₋₃烷基羰基、甲氧基或被一个或两个 C₁₋₆ 烷基或 C₂₋₇ 烷酰基任选取代的氨基;或
R₁ 和 R₂ 与它们所连接的碳原子一起形成 2,1,3-噁二唑或三唑;R₃ 和 R₄ 中的一个是氢或 C₁₋₄ 烷基,另一个是 C₁₋₄ 烷基;或
R₃ 和 R₄ 合在一起是 C₂₋₅ 聚亚甲基;
R₅ 是氢、羟基、C₁₋₆ 烷氧基、C₁₋₇酰氧基或 ONO₂;
R₆ 是氢或 C₁₋₆ 烷基;以及
R₇ 是卤素、氨基或甲氨基;
是 K⁺ 通道激活剂,可用于治疗高血压和呼吸道疾病。